Table 14.
Blood pressure |
TCVR |
||||||
---|---|---|---|---|---|---|---|
BP values at 90 days |
Achieving BP control at 90 days |
Improvement |
Achieving |
||||
SBP | DBP | SBP | DBP | SBP/DBP | In score | Improvement | |
Patient-related variables | |||||||
Demographics | |||||||
Age | − | + | − | + | − | + | |
Male gender | − | + | + | + | |||
Female gender | + | ||||||
Blood pressure | |||||||
SBP at initial diagnosis of hypertension | − | − | − | − | |||
SBP at baseline | − | − | − | − | |||
Controlled SBP at baseline | + | ||||||
DBP at initial diagnosis of hypertension | − | − | |||||
DBP at baseline | − | ||||||
Controlled DBP at baseline | + | ||||||
Uncontrolled DBP at baseline | − | ||||||
Controlled SBP and DBP at baseline | + | + | |||||
Risk factors: general | |||||||
Conditions and risk factors: no pre-existing | + | + | + | + | + | ||
Highly vulnerable to uncontrolled hypertension cluster | − | − | − | − | − | ||
Risk factors: metabolic | |||||||
Diabetes | − | − | − | + | |||
Conditions and risk factors: diabetes | − | − | − | − | |||
Retinopathy | − | ||||||
Obesity | − | − | |||||
Risk factors: cardiovascular | |||||||
Conditions and risk factors: myocardial infarction | − | ||||||
Risk factors: lipids | |||||||
Hypercholesterolemia | − | − | |||||
Total cholesterol at baseline | − | ||||||
Conditions and risk factors: dyslipidemia | − | − | |||||
Risk factors: lifestyle | |||||||
Conditions and risk factors: smoker | - | − | |||||
Total cardiovascular risk | |||||||
Low added risk | + | ||||||
Moderate added risk | − | + | + | ||||
High added risk | + | − | − | + | + | ||
Very high added risk | + | − | − | + | + | ||
Concomitant antihypertensive treatment | |||||||
ACE inhibitor | + | + | |||||
Other concomitant treatment | |||||||
Lipid-lowering | + | ||||||
Medication behavior | |||||||
Nonadherent days in past 4 weeks | − | − | − | − | |||
Patient-reported nonadherence behavior | − | − | − | − | − | ||
Patient-reported adherence behavior | + | ||||||
Patient-rated adherence | + | + | |||||
Physician-rated adherence | + | + | + | + | + | + | + |
Blood pressure monitoring | |||||||
Days since last blood pressure measurement | − | ||||||
Months since last blood pressure measurement | − | − | |||||
Physician-related variables | |||||||
Education | |||||||
Years since medical school graduation (in practice) | − | − | − | − | − | ||
Experience with hypertension | |||||||
Hypertensive patients seen in past 12 months | + | + | + | + | |||
Knowledge regarding hypertension management | |||||||
Correct blood pressure targets for non-diabetic patients | + | + | |||||
Evidence-based practice patterns | |||||||
Self-reported practices consistent with evidence-based guidelines re: SBP threshold for treatment initiation | + | + | + | ||||
Self-reported practices consistent with evidence-based guidelines re: SBP threshold for treatment intensification | + | + | + | ||||
Self-reported practices consistent with evidence-based guidelines re: DBP threshold for treatment initiation | + | + | |||||
Self-reported practices consistent with evidence-based guidelines re: DBP threshold for treatment intensification | + | + | |||||
Clinical practice | |||||||
Visits typically scheduled by physician with newly diagnosed hypertension patient in first 3 months | + | ||||||
Physician routinely calculates overall cardiovascular risk of patients | + |
Notes:
Negative impact is denoted by a minus (−) sign: increases BP levels, increases odds of uncontrolled BP, decreases change in TCVR, and decreases odds of achieving a reduction in TCVR. Positive impact is denoted by a plus (+) sign: decreases BP levels, decreases odds of uncontrolled BP, increases change in TCVR, and increases odds of achieving a reduction in TCVR.
Abbreviation: ACE, angiotensin converting enzyme.